A Phase 3 interventional study of Esomeprazole and Ranitidine in NSAID Associated Gastric Ulcers, sponsored by AstraZeneca. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-01-25.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing esomeprazole in Stomach Ulcer — none open to participants now, none under way, none of them phase 3. Esomeprazole · Stomach Ulcer.
Among the 11 studies testing esomeprazole in Stomach Ulcer, this one is the 5th largest by planned enrollment, is one of 4 that started in 2001, is one of 9 in phase 3, and was the 6th registered.
116 studies on the registry are indexed under Stomach Ulcer; 13 are open to participants now.
Browse Stomach Ulcer studies →None of the 11 studies testing esomeprazole in Stomach Ulcer is open now. The open studies under Stomach Ulcer, anywhere →
Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 10 Stomach Ulcer studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 4 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 298 across 88 interventional studies indexed under Stomach Ulcer.
Median enrollment 400 across the 11 interventional studies. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 2 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
17 studies in Stomach Ulcer by AstraZeneca: none open now, none under way, none of them phase 3. Of 17 finished, 7 (41%) have results posted.
Among the 17 studies in Stomach Ulcer by AstraZeneca, this one is the 5th largest by planned enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2001, is one of 11 in phase 3, and was the 6th registered.
AstraZeneca’s Stomach Ulcer studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing esomeprazole in Stomach Ulcer, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 17 in Stomach Ulcer:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Nonsteroidal anti-inflammatory drugs (NSAIDS) are often associated with gastric ulcers. This study looks at the treatment of these gastric ulcers with one of the three following treatment groups: esomeprazole 40 mg once daily; esomeprazole 20 mg once daily; or ranitidine 150 mg twice daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
20mg Oral tablet daily
Drug: Esomeprazole
40mg oral tablet daily
Drug: Esomeprazole
150mg oral twice daily
Drug: Ranitidine
20mg Oral tablet once daily
Also known as: Nexium
150mg oral twice daily
Also known as: Zantac
40mg oral tablet once daily
Also known as: Nexium
To assess the safety and efficacy of esomeprazole 40 mg qd versus ranitidine 150 mg bid through 8 weeks of treatment for the healing of gastric ulcers in patients receiving daily NSAID therapy. Healing is defined as the absence of gastric ulcers.
Patient and investigator assessed GI symptoms for up to 8 weeks of treatment.
Time frame: Assessments at week 0, week 4 and week 8
Safety and tolerability of the treatments for 8 weeks of treatment.
Time frame: Assessments at week 0, week 4 and week 8
No study locations are listed for this record.
The record gives a start of Feb 2001, a primary completion of Oct 2003 and a completion of Oct 2003. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esomeprazole